ARTL
Price
$10.05
Change
-$0.98 (-8.88%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
5.19M
34 days until earnings call
PRVCF
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Jul 2 closing price
Capitalization
12.58M
Interact to see
Advertisement

ARTL vs PRVCF

Header iconARTL vs PRVCF Comparison
Open Charts ARTL vs PRVCFBanner chart's image
Artelo Biosciences
Price$10.05
Change-$0.98 (-8.88%)
Volume$957
Capitalization5.19M
PreveCeutical Medical
Price$0.02
Change-$0.00 (-0.00%)
Volume$142.31K
Capitalization12.58M
ARTL vs PRVCF Comparison Chart in %
Loading...
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRVCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTL vs. PRVCF commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Buy and PRVCF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (ARTL: $11.03 vs. PRVCF: $0.02)
Brand notoriety: ARTL and PRVCF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 81% vs. PRVCF: 289%
Market capitalization -- ARTL: $5.19M vs. PRVCF: $12.58M
ARTL [@Biotechnology] is valued at $5.19M. PRVCF’s [@Biotechnology] market capitalization is $12.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 0 FA rating(s) are green whilePRVCF’s FA Score has 0 green FA rating(s).

  • ARTL’s FA Score: 0 green, 5 red.
  • PRVCF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARTL is a better buy in the long-term than PRVCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 7 TA indicator(s) are bullish while PRVCF’s TA Score has 2 bullish TA indicator(s).

  • ARTL’s TA Score: 7 bullish, 3 bearish.
  • PRVCF’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ARTL is a better buy in the short-term than PRVCF.

Price Growth

ARTL (@Biotechnology) experienced а +80.08% price change this week, while PRVCF (@Biotechnology) price change was -0.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

ARTL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRVCF($12.6M) has a higher market cap than ARTL($5.19M). ARTL YTD gains are higher at: 73.428 vs. PRVCF (35.326). PRVCF has higher annual earnings (EBITDA): -1.36M vs. ARTL (-9.9M). ARTL has more cash in the bank: 746K vs. PRVCF (5.48K). ARTL has less debt than PRVCF: ARTL (95K) vs PRVCF (4.6M). ARTL (0) and PRVCF (0) have equivalent revenues.
ARTLPRVCFARTL / PRVCF
Capitalization5.19M12.6M41%
EBITDA-9.9M-1.36M726%
Gain YTD73.42835.326208%
P/E RatioN/AN/A-
Revenue00-
Total Cash746K5.48K13,626%
Total Debt95K4.6M2%
FUNDAMENTALS RATINGS
ARTL vs PRVCF: Fundamental Ratings
ARTL
PRVCF
OUTLOOK RATING
1..100
9759
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3642
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTL's Valuation (63) in the null industry is in the same range as PRVCF (87). This means that ARTL’s stock grew similarly to PRVCF’s over the last 12 months.

ARTL's Profit vs Risk Rating (100) in the null industry is in the same range as PRVCF (100). This means that ARTL’s stock grew similarly to PRVCF’s over the last 12 months.

ARTL's SMR Rating (99) in the null industry is in the same range as PRVCF (100). This means that ARTL’s stock grew similarly to PRVCF’s over the last 12 months.

ARTL's Price Growth Rating (36) in the null industry is in the same range as PRVCF (42). This means that ARTL’s stock grew similarly to PRVCF’s over the last 12 months.

ARTL's P/E Growth Rating (100) in the null industry is in the same range as PRVCF (100). This means that ARTL’s stock grew similarly to PRVCF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLPRVCF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
86%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRVCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BOWN10.200.75
+7.94%
Bowen Acquisition Corp
FC24.171.35
+5.92%
Franklin Covey Company
AOS68.090.33
+0.49%
AO Smith Corp
KWE10.85N/A
N/A
Kwesst Micro Systems Inc
TNDM17.08-0.16
-0.93%
Tandem Diabetes Care

PRVCF and

Correlation & Price change

A.I.dvisor tells us that PRVCF and BPTSY have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRVCF and BPTSY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRVCF
1D Price
Change %
PRVCF100%
N/A
BPTSY - PRVCF
21%
Poorly correlated
+5.07%
GLMD - PRVCF
20%
Poorly correlated
-2.17%
ARTL - PRVCF
20%
Poorly correlated
+16.11%
SBHMY - PRVCF
9%
Poorly correlated
N/A
PXXLF - PRVCF
7%
Poorly correlated
N/A
More